Advertisement

November 1, 2019

CMS 2020 Final Hospital Outpatient Rule Allows Reimbursement of PCI in Ambulatory Centers

November 1, 2019—The American College of Cardiology (ACC) announced that the Centers for Medicare and Medicaid Services (CMS) will release the 2020 Medicare Physician Fee Schedule final rule addressing Medicare payment and quality provisions for physicians in 2020, under which, physicians will see a virtually flat conversion factor on January 1, 2020, going from $36.04 to $36.09. The final version of the document is scheduled to be published on November 15, 2019. 

CMS estimates that the physician rule will maintain overall payment to cardiologists from 2019 to 2020 through updates to work, practice expense, and malpractice relative value units. This estimate is based on the entire cardiology profession and can vary widely depending on the mix of services provided in a practice. In July, the ACC announced the release of the proposed 2020 fee schedule and outpatient rules and presented a summary of the document.

Among the many items addressed in the final document, the ACC highlighted that the hospital outpatient rule includes the addition of CPT codes describing angioplasty and percutaneous coronary interventions with stenting to the Ambulatory Surgery Center Covered Procedures list for 2020, reflecting the feedback of ACC and other stakeholders, noted the society.

In addition to the Physician Fee Schedule, the 2020 Hospital Outpatient Prospective Payment System final rule is scheduled to be published on November 12, 2019. The outpatient rule indicates a 2.6% payment update for hospitals and other proposals.

The CMS fact sheet is available online here: Finalized Policy, Payment, and Quality Provisions Changes to the Medicare Physician Fee Schedule for Calendar Year 2020. ACC also posted online the CMS 2020 Quality Payment Program Final Rule Overview Fact Sheet.

Advertisement


November 6, 2019

Edwards' Sapien 3 TAVR System Approved in Europe for Low-Risk Patients

October 31, 2019

Study Evaluates Outcomes of TAVR in Mixed Aortic Valve Disease